LRRK2 G2019S kinase inhibitor

**LRRK2 G2019S kinase inhibitor** most specifically refers to **EB-42168**, an investigational, mutant-selective **small-molecule** inhibitor of leucine-rich repeat serine/threonine-protein kinase 2 engineered to preferentially inhibit the pathogenic **G2019S** LRRK2 variant associated with familial and sporadic Parkinson's disease. Preclinical studies showed selective suppression of G2019S-linked LRRK2 phosphorylation and reversal of mitochondrial DNA damage phenotypes in patient-derived cells, supporting a precision-medicine strategy for **LRRK2-associated Parkinson's disease** while potentially sparing wild-type LRRK2 activity. Publicly available summaries also indicate that Escape Bio advanced a mutant-selective LRRK2 G2019S inhibitor into IND-enabling development, but broad clinical-stage details and commercial product information remain limited.

Other names

G2019S selective LRRK2 kinase inhibitorG-2019S selective LRRK2 kinase inhibitorG 2019S selective LRRK2 kinase inhibitorG2019S mutant LRRK2 kinase inhibitorG-2019S mutant LRRK2 kinase inhibitorG 2019S mutant LRRK2 kinase inhibitormutant-selective LRRK2 G2019S kinase inhibitor